September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Claudia Vasconcelos: DESTINY-Breast09 results could be practice-changing for patients with HER2+ MBC
Apr 23, 2025, 16:07

Claudia Vasconcelos: DESTINY-Breast09 results could be practice-changing for patients with HER2+ MBC

Claudia Vasconcelos, Sr. Medical Director, Global Head, Breast and Gyn TA at Parexel, shared a post on LinkedIn:

“Sharing the positive topline results from DESTINY-Breast09!

Trastuzumab deruxtecan (T-DXd) in combination with pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in PFS compared to taxane, trastuzumab and pertuzumab (THP) as 1st-line treatment for patients with HER2-positive metastatic breast cancer.

A protential practice-changing study for HER2+ MBC!”